3 Trade Groups Vehemently Oppose “Huge Seller” Drug Re-Pricing, Say It Will Hobble Innovation

December 10, 2015
Three major pharma industry groups on December 9 articulated their staunch opposition to the proposed re-pricing of drugs generating “huge sales,” lashing out at the rule as being an obstacle to innovation, but their call failed to resonate with healthcare...read more